Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01659931 · ClinicalTrials.gov registry record · Early Phase 1

Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted Conditions

A Early Phase 1 study of Asthma, sponsored by Roxane Laboratories.

Completed
Registry status
Early Phase 1
Development phase
34
Enrollment target
1
Study location

NCT01659931: Completed Early Phase 1 study of Asthma, sponsored by Roxane Laboratories.

NCT01659931 is a Early Phase 1 study of Asthma that has completed, run by Roxane Laboratories. The registered enrollment target is 34 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01659931, a Early Phase 1 study of Asthma, has completed, sponsored by Roxane Laboratories.

COMPLETED
Registry status
Early Phase 1
Development phase
34 participants
Enrollment target
1
Study location

Study Summary

The objective of this study was to prove the bioequivalence of Montelukast Tablet under fasted conditions

Conditions Studied

Interventions

  • DRUG Montelukast
  • DRUG Singulair

Study Locations (1)

North Dakota

  • PRACS Institute, Ltd. - Fargo

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2008-02
Est. Completion 2008-02
Phase Early Phase 1
Roxane Laboratories

93 total trials

What the finished NCT01659931 record still lists

NCT01659931 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Montelukast is the first listed.

NCT01659931 reports a single indexed study location in North Dakota.

Frequently Asked Questions

What is clinical trial NCT01659931 about?

NCT01659931 is a clinical study titled "Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted Conditions". The objective of this study was to prove the bioequivalence of Montelukast Tablet under fasted conditions

What is the current status of trial NCT01659931?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 34 participants. The study started on 2008-02. Estimated completion is 2008-02.

What conditions does trial NCT01659931 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT01659931?

The interventions under investigation include: Montelukast (DRUG), Singulair (DRUG).

Who is sponsoring clinical trial NCT01659931?

This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01659931 being conducted?

This trial has 1 study location across North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01659931's enrollment target sits among peer trials

34 295th of 374 higher than 80 of 374 other Asthma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01659931, the US trial registry maintained by the National Library of Medicine. NCT01659931 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.